#403 ‒ Peptides: separating scientific promise from marketing hype

Peptides have garnered significant attention in the health and wellness space, often marketed as cutting-edge regenerative therapies for everything from muscle repair to longevity. However, the enthusiasm surrounding peptides is often fueled by misinformation and aggressive commercialization. In this episode of The Drive, Peter Attia and Nick Stenson delve into the complex world of peptides, offering a critical framework for evaluating their efficacy and safety.

The Problem with "Peptides"

Peter begins by highlighting a fundamental issue: the term "peptide" itself is almost meaningless when it comes to assessing a molecule's safety or effectiveness. He explains that a peptide is simply a short chain of amino acids. Some peptides, like insulin and GLP-1 agonists, are among the most important drugs ever developed, backed by robust scientific evidence. Others, however, have essentially no credible evidence behind them. The word "peptide" is a chemical description, not a mark of quality. Peter argues that the marketing success of the last decade has been convincing people otherwise, by distilling a diverse group of molecules into a single, seemingly naturalistic term. This conveys a sense of safety and effectiveness by default, which is often misleading.

Peter emphasizes that peptides are, in fact, drugs. Furthermore, most of what is being sold as "natural" peptides are actually synthetically modified versions of natural molecules, engineered to bind more tightly to receptors, last longer in the body, or hit targets that the original protein could not. Therefore, instead of asking a simple question like "Do peptides work?", Peter suggests we need to ask multiple, specific questions about individual peptides.